NovoCure Ltd. (NASDAQ:NVCR) shares traded up 3.4% during trading on Thursday . The stock traded as high as $8.14 and last traded at $8.02, with a volume of 158,955 shares. The stock had previously closed at $7.76.

Several research analysts recently commented on the stock. JMP Securities cut their price objective on shares of NovoCure from $43.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, July 29th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of NovoCure in a report on Tuesday, May 10th. Barclays PLC cut their price objective on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Friday, July 29th. Deutsche Bank AG cut their price objective on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating for the company in a report on Friday, July 29th. Finally, Zacks Investment Research downgraded shares of NovoCure from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $21.43.

The stock’s market capitalization is $684.48 million. The company’s 50-day moving average is $9.78 and its 200 day moving average is $11.94.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.11. The firm had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $15.90 million. On average, analysts anticipate that NovoCure Ltd. will post ($1.82) earnings per share for the current year.

In other news, COO Michael J. Ambrogi sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the transaction, the chief operating officer now directly owns 324,084 shares of the company’s stock, valued at $3,966,788.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gert L. Perlhagen sold 676,576 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $1.85, for a total transaction of $1,251,665.60. Following the transaction, the director now directly owns 676,576 shares of the company’s stock, valued at $1,251,665.60. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.